Last reviewed · How we verify
Pyelonephritis
Approved treatments
- Doribax · Shionogi
- Test formulation (Treatment A) · Pfizer
- Avycaz · Cerexa Inc
EMBLAVEO is an antibacterial drug. - Recarbrio · Merck & Co.
Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria. - Fetroja · Shionogi
Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death. - Noroxin
- Floxin
- Levaquin · Generic (originally Daiichi Sankyo/J&J)
Levofloxacin is a fluoroquinolone antibacterial agent. - Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Pyelonephritis patent landscape — cliff calendar, originator estates, attackable patents
- Pyelonephritis treatment landscape brief
- Pyelonephritis treatment updates RSS
Frequently asked questions about Pyelonephritis
What drugs treat Pyelonephritis?
Tracked treatments include Doribax, Test formulation (Treatment A), Avycaz, Recarbrio, Fetroja, Noroxin, Floxin, Levaquin.
What is the treatment for Pyelonephritis?
Standard treatment for Pyelonephritis includes Doribax, Test formulation (Treatment A), Avycaz, Recarbrio, Fetroja. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Pyelonephritis patent cliff · Pyelonephritis CI report
- Treatment: Doribax · Shionogi
- Treatment: Test formulation (Treatment A) · Pfizer
- Treatment: Avycaz · Cerexa Inc
- Treatment: Recarbrio · Merck & Co.
- Treatment: Fetroja · Shionogi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing